Abstract
WhenIstartedmycareerinleukemiaresearch,interferonalfa was standard therapy for patients with chronic myeloid leukemia (CML). Interferon could induce complete cytogenetic response (CCyR; ie, 0% Philadelphia-chromosome metaphases) or partial cytogenetic response (PCyR; ie, 1% to 35%), and such responses were associated with improved survival. These responses, particularly CCyR, occurred only in a minority of patients and the time to response was not given much attention. With the introduction of tyrosine kinase inhibitors (TKIs), our goals became more ambitious,
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
